Boswellia serrata is a tree native to India, from which it is extracted a gum-resin formed by about 16% from an essential oil that contains boswellic acids, terpenes and polysaccharides.
Boswellic acids exert a selective inhibition on the enzyme lipoxygenase, which stimulates the production of endogenous substances (Leukotrienes) that facilitate inflammatory processes, thus reducing their levels in the blood.
Moreover, a component in particular (AKBA, an acetylated boswellic acid) inhibits elastases, proteolytic enzymes that attack and demolish the elastic tissue component where an inflammation is present.
Boswellic acids play a strong anti-inflammatory action acting with a mechanism similar to a non-steroidal anti-inflammatory drug (NSAID). They also associate pain relief, antiallergic and healing actions to the powerful antiinflammatory one.
Serrasol is an Asoltech product based on a dry extract of Boswellia serrata, associated with materials selected for their physical and chemical properties and treated with SOL-MEX technology.
In our R&D laboratories we also carried out analytical studies to identify the best starting extract , where all boswellic acids must be represented to ensure a synergistic effect.
In the extract used for Serrasol boswellic acids (inhibiting Lipoxygenase) are well represented in comparison with other extracts on the market. At the same time, a good concentration in AKBA (acetylated boswellic acid) ensures a synergistic effect (elastase inhibition).
In addition, in Serrasol was introduced another cooperative component (Ammonium Glycyrrhizate), derived from a soluble extract of licorice, which combines antinflammatory activity with a pleasant sweet taste.
Serrasol allows the passage in solution of active components of Boswellia in concentrations otherwise unreachable: about 15 times greater than the native extract.
The stability of SERRASOL was evaluated in 2 ICH conditions (25° C + 60% RH and 40° C + 75% RH) and under normal storage conditions; it resulted perfectly stable for all considered parameters. To date it reached 48 months of retest date from date of manufacture.
It is also currently under evaluation an experimental in-vitro protocol, conducted in collaboration with the DipSciVita of the University of Trieste, in order to assess the antinflammatory activity of Serrasol in comparison with the native extract.
SERRASOL properties can be exploited using the ingredient in products designed for different target groups.
For example, SERRASOL can be formulated with synergistic ingredients to design products useful as adjuvants in situations of:
- joint inflammation
- irritable bowel syndrome
- to soothe oral inflammation
- to ease the pain and swelling associated with arthritis, bursitis and tendonitis